Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Advancing nonclinical innovation and safety in pharmaceutical testing.

Baker EJ, Beck NA, Berg EL, Clayton-Jeter HD, Chandrasekera PC, Curley JL, Donzanti BA, Ewart LC, Gunther JM, Kenna JG, LeCluyse EL, Liebman MN, Pugh CL, Watkins PB, Sullivan KM.

Drug Discov Today. 2018 Nov 20. pii: S1359-6446(18)30264-2. doi: 10.1016/j.drudis.2018.11.011. [Epub ahead of print] Review.

2.

Dose-response in a high density three-dimensional liver device with real-time bioenergetic and metabolic flux quantification.

Tikunov AP, Shim YS, Bhattarai N, Siler SQ, Soldatow V, LeCluyse EL, McDunn JE, Watkins PB, Macdonald JM.

Toxicol In Vitro. 2017 Dec;45(Pt 1):119-127. doi: 10.1016/j.tiv.2017.08.021. Epub 2017 Sep 1.

PMID:
28867505
3.
4.

Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues.

Norona LM, Nguyen DG, Gerber DA, Presnell SC, LeCluyse EL.

Toxicol Sci. 2016 Dec;154(2):354-367. Epub 2016 Sep 7.

5.

Subtoxic Alterations in Hepatocyte-Derived Exosomes: An Early Step in Drug-Induced Liver Injury?

Holman NS, Mosedale M, Wolf KK, LeCluyse EL, Watkins PB.

Toxicol Sci. 2016 Jun;151(2):365-75. doi: 10.1093/toxsci/kfw047. Epub 2016 Mar 8.

6.

Co-culture of Hepatocytes and Kupffer Cells as an In Vitro Model of Inflammation and Drug-Induced Hepatotoxicity.

Rose KA, Holman NS, Green AM, Andersen ME, LeCluyse EL.

J Pharm Sci. 2016 Feb;105(2):950-964. doi: 10.1016/S0022-3549(15)00192-6.

7.

Liver biomarker and in vitro assessment confirm the hepatic origin of aminotransferase elevations lacking histopathological correlate in beagle dogs treated with GABAA receptor antagonist NP260.

Harrill AH, Eaddy JS, Rose K, Cullen JM, Ramanathan L, Wanaski S, Collins S, Ho Y, Watkins PB, Lecluyse EL.

Toxicol Appl Pharmacol. 2014 Jun 1;277(2):131-7. doi: 10.1016/j.taap.2014.03.015. Epub 2014 Mar 31.

PMID:
24699182
8.

A micropatterned hepatocyte coculture model for assessment of liver toxicity using high-content imaging analysis.

Trask OJ Jr, Moore A, LeCluyse EL.

Assay Drug Dev Technol. 2014 Jan-Feb;12(1):16-27. doi: 10.1089/adt.2013.525. Epub 2014 Jan 20.

PMID:
24444127
9.

Development of 3D dynamic flow model of human liver and its application to prediction of metabolic clearance of 7-ethoxycoumarin.

Choi K, Pfund WP, Andersen ME, Thomas RS, Clewell HJ, LeCluyse EL.

Tissue Eng Part C Methods. 2014 Aug;20(8):641-51. doi: 10.1089/ten.TEC.2013.0562. Epub 2014 Mar 4.

PMID:
24294911
10.

A map of the PPARα transcription regulatory network for primary human hepatocytes.

McMullen PD, Bhattacharya S, Woods CG, Sun B, Yarborough K, Ross SM, Miller ME, McBride MT, LeCluyse EL, Clewell RA, Andersen ME.

Chem Biol Interact. 2014 Feb 25;209:14-24. doi: 10.1016/j.cbi.2013.11.006. Epub 2013 Nov 22.

11.

Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

Pedersen JM, Matsson P, Bergström CA, Hoogstraate J, Norén A, LeCluyse EL, Artursson P.

Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6.

12.

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gómez-Lechón MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Häussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhütter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stöber R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG.

Arch Toxicol. 2013 Aug;87(8):1315-530. doi: 10.1007/s00204-013-1078-5. Epub 2013 Aug 23. Review.

13.

Bioactivation and toxicity of acetaminophen in a rat hepatocyte micropatterned coculture system.

Ukairo O, McVay M, Krzyzewski S, Aoyama S, Rose K, Andersen ME, Khetani SR, Lecluyse EL.

J Biochem Mol Toxicol. 2013 Oct;27(10):471-8. doi: 10.1002/jbt.21512. Epub 2013 Aug 5.

PMID:
23918466
14.

Knockout of the aryl hydrocarbon receptor results in distinct hepatic and renal phenotypes in rats and mice.

Harrill JA, Hukkanen RR, Lawson M, Martin G, Gilger B, Soldatow V, Lecluyse EL, Budinsky RA, Rowlands JC, Thomas RS.

Toxicol Appl Pharmacol. 2013 Oct 15;272(2):503-18. doi: 10.1016/j.taap.2013.06.024. Epub 2013 Jul 13.

PMID:
23859880
15.

In vitro models for liver toxicity testing.

Soldatow VY, Lecluyse EL, Griffith LG, Rusyn I.

Toxicol Res (Camb). 2013 Jan 1;2(1):23-39. Epub 2012 Nov 23.

16.

Hemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro.

Dash A, Simmers MB, Deering TG, Berry DJ, Feaver RE, Hastings NE, Pruett TL, LeCluyse EL, Blackman BR, Wamhoff BR.

Am J Physiol Cell Physiol. 2013 Jun 1;304(11):C1053-63. doi: 10.1152/ajpcell.00331.2012. Epub 2013 Mar 13.

17.

Long-term stability of primary rat hepatocytes in micropatterned cocultures.

Ukairo O, Kanchagar C, Moore A, Shi J, Gaffney J, Aoyama S, Rose K, Krzyzewski S, McGeehan J, Andersen ME, Khetani SR, Lecluyse EL.

J Biochem Mol Toxicol. 2013 Mar;27(3):204-12. doi: 10.1002/jbt.21469. Epub 2013 Jan 11.

PMID:
23315828
18.

A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes.

Smith CM, Nolan CK, Edwards MA, Hatfield JB, Stewart TW, Ferguson SS, Lecluyse EL, Sahi J.

J Pharm Sci. 2012 Oct;101(10):3989-4002. doi: 10.1002/jps.23262. Epub 2012 Jul 17.

PMID:
22806329
19.

Organotypic liver culture models: meeting current challenges in toxicity testing.

LeCluyse EL, Witek RP, Andersen ME, Powers MJ.

Crit Rev Toxicol. 2012 Jul;42(6):501-48. doi: 10.3109/10408444.2012.682115. Epub 2012 May 15. Review.

20.

Cross-species comparisons of transcriptomic alterations in human and rat primary hepatocytes exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Black MB, Budinsky RA, Dombkowski A, Cukovic D, LeCluyse EL, Ferguson SS, Thomas RS, Rowlands JC.

Toxicol Sci. 2012 May;127(1):199-215. doi: 10.1093/toxsci/kfs069. Epub 2012 Feb 1.

PMID:
22298810
21.

Evaluation of an in vitro toxicogenetic mouse model for hepatotoxicity.

Martinez SM, Bradford BU, Soldatow VY, Kosyk O, Sandot A, Witek R, Kaiser R, Stewart T, Amaral K, Freeman K, Black C, LeCluyse EL, Ferguson SS, Rusyn I.

Toxicol Appl Pharmacol. 2010 Dec 15;249(3):208-16. doi: 10.1016/j.taap.2010.09.012. Epub 2010 Sep 24.

22.

Human and rat primary hepatocyte CYP1A1 and 1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran.

Budinsky RA, LeCluyse EL, Ferguson SS, Rowlands JC, Simon T.

Toxicol Sci. 2010 Nov;118(1):224-35. doi: 10.1093/toxsci/kfq238. Epub 2010 Aug 12.

PMID:
20705892
23.

Isolation and culture of primary hepatocytes from resected human liver tissue.

Lecluyse EL, Alexandre E.

Methods Mol Biol. 2010;640:57-82. doi: 10.1007/978-1-60761-688-7_3.

PMID:
20645046
24.

Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening.

Rotroff DM, Wetmore BA, Dix DJ, Ferguson SS, Clewell HJ, Houck KA, Lecluyse EL, Andersen ME, Judson RS, Smith CM, Sochaski MA, Kavlock RJ, Boellmann F, Martin MT, Reif DM, Wambaugh JF, Thomas RS.

Toxicol Sci. 2010 Oct;117(2):348-58. doi: 10.1093/toxsci/kfq220. Epub 2010 Jul 16. Erratum in: Toxicol Sci. 2014 Feb;137(2):499. Dosage error in article text.

25.

Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals.

Rotroff DM, Beam AL, Dix DJ, Farmer A, Freeman KM, Houck KA, Judson RS, LeCluyse EL, Martin MT, Reif DM, Ferguson SS.

J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):329-46. doi: 10.1080/10937404.2010.483949.

PMID:
20574906
26.

Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.

Sahi J, Shord SS, Lindley C, Ferguson S, LeCluyse EL.

J Biochem Mol Toxicol. 2009 Jan-Feb;23(1):43-58. doi: 10.1002/jbt.20264.

PMID:
19202563
27.

Primary human hepatocyte culture for HCV study.

Zhu H, Elyar J, Foss R, Hemming A, Hall E, Lecluyse EL, Liu C.

Methods Mol Biol. 2009;510:373-82. doi: 10.1007/978-1-59745-394-3_28.

PMID:
19009276
28.

Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations.

Hewitt NJ, Lecluyse EL, Ferguson SS.

Xenobiotica. 2007 Oct-Nov;37(10-11):1196-224. Review.

PMID:
17968743
29.

Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers.

Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, Wang H.

J Pharmacol Exp Ther. 2007 Jan;320(1):72-80. Epub 2006 Oct 13.

30.

Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel.

Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, Yan B.

J Pharmacol Exp Ther. 2006 Dec;319(3):1477-84. Epub 2006 Sep 11.

31.

Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol.

Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, Yan B.

J Pharmacol Exp Ther. 2006 Dec;319(3):1467-76. Epub 2006 Aug 30.

32.

Cloning, tissue expression, and regulation of beagle dog CYP4A genes.

Graham RA, Goodwin B, Merrihew RV, Krol WL, Lecluyse EL.

Toxicol Sci. 2006 Aug;92(2):356-67. Epub 2006 May 4.

PMID:
16675513
33.

Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes.

Graham RA, Tyler LO, Krol WL, Silver IS, Webster LO, Clark P, Chen L, Banks T, LeCluyse EL.

J Biochem Mol Toxicol. 2006;20(2):69-78.

PMID:
16615094
34.

Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor.

Faucette SR, Sueyoshi T, Smith CM, Negishi M, Lecluyse EL, Wang H.

J Pharmacol Exp Ther. 2006 Jun;317(3):1200-9. Epub 2006 Mar 2.

35.

Differential UGT1A1 induction by chrysin in primary human hepatocytes and HepG2 Cells.

Smith CM, Graham RA, Krol WL, Silver IS, Negishi M, Wang H, Lecluyse EL.

J Pharmacol Exp Ther. 2005 Dec;315(3):1256-64. Epub 2005 Aug 31.

36.
37.

Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers.

Smith CM, Faucette SR, Wang H, LeCluyse EL.

J Biochem Mol Toxicol. 2005;19(2):96-108.

PMID:
15849716
38.

Interindividual variation in the metabolism of arsenic in cultured primary human hepatocytes.

Drobná Z, Waters SB, Walton FS, LeCluyse EL, Thomas DJ, Stýblo M.

Toxicol Appl Pharmacol. 2004 Dec 1;201(2):166-77.

PMID:
15541756
39.

The human sulfotransferase SULT1A1 gene is regulated in a synergistic manner by Sp1 and GA binding protein.

Hempel N, Wang H, LeCluyse EL, McManus ME, Negishi M.

Mol Pharmacol. 2004 Dec;66(6):1690-701. Epub 2004 Sep 21.

40.

Isolation and culture of primary human hepatocytes.

LeCluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S, Richert L.

Methods Mol Biol. 2005;290:207-29.

PMID:
15361665
41.

Effects of avasimibe on cytochrome P450 2C9 expression in vitro and in vivo.

Sahi J, Stern RH, Milad MA, Rose KA, Gibson G, Zheng X, Stilgenbauer L, Sadagopan N, Jolley S, Gilbert D, LeCluyse EL.

Drug Metab Dispos. 2004 Dec;32(12):1370-6. Epub 2004 Aug 27.

42.
43.

Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes.

Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD.

Drug Metab Dispos. 2004 Mar;32(3):359-63.

44.

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers.

Faucette SR, Wang H, Hamilton GA, Jolley SL, Gilbert D, Lindley C, Yan B, Negishi M, LeCluyse EL.

Drug Metab Dispos. 2004 Mar;32(3):348-58.

45.

Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes.

Wang H, LeCluyse EL.

Clin Pharmacokinet. 2003;42(15):1331-57. Review.

PMID:
14674787
46.

CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans.

Tippin TK, Hamilton G, Moore L, Beaudet EJ, Jolley S, Brodie TA, Andrews RC, Becherer JD, McDougald DL, Gaul MD, Hoivik DJ, Mellon-Kusibab K, Lehmann J, Kliewer S, Novick S, Laethem R, Zhao Z, LeCluyse EL.

Drug Metab Dispos. 2003 Jul;31(7):870-7.

47.

Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor.

Sahi J, Milad MA, Zheng X, Rose KA, Wang H, Stilgenbauer L, Gilbert D, Jolley S, Stern RH, LeCluyse EL.

J Pharmacol Exp Ther. 2003 Sep;306(3):1027-34. Epub 2003 May 23.

48.

Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes.

Wang H, Faucette SR, Gilbert D, Jolley SL, Sueyoshi T, Negishi M, LeCluyse EL.

Drug Metab Dispos. 2003 May;31(5):620-30.

49.

Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.

Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW.

Drug Metab Dispos. 2003 Apr;31(4):439-46.

50.

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.

Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A.

Drug Metab Dispos. 2003 Apr;31(4):421-31.

Supplemental Content

Loading ...
Support Center